In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
about
Micafungin in the treatment of invasive candidiasis and invasive aspergillosisOccidiofungin's chemical stability and in vitro potency against Candida species.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureTreatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.KRE5 Suppression Induces Cell Wall Stress and Alternative ER Stress Response Required for Maintaining Cell Wall Integrity in Candida glabrataIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Anidulafungin--state of affairs from a clinical perspective.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.Echinocandin pharmacodynamics: review and clinical implications.Anidulafungin: an evidence-based review of its use in invasive fungal infections.Anidulafungin: when and how? The clinician's view.Echinocandins: are they all the same?Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Echinocandins: The Expanding Antifungal Armamentarium.Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
P2860
Q35026516-C76EFE7E-D819-4E62-9CB4-1DC93716317DQ35689277-2E4DD1DC-3BD4-477C-AB4F-1B184B0187B5Q35959484-1EF3FD29-8FBB-4B46-860D-1E31EE0EFF3BQ35959489-F3867B2C-584F-49CD-A34A-BFB54FAF5B75Q36109051-03A671BF-A1B9-49A7-8692-51439E0E3010Q36425025-552E0954-DAF9-4E4F-8A14-0CB8F31FC8B4Q36774257-2DFFEB87-5FB2-421D-BA83-F98A8870E5E0Q36828156-12A40596-F7FF-481E-BBCD-1E4C18DC1D09Q36932989-BCF84FC0-B8EB-41A5-B999-893731D79341Q36933000-FF46D556-ED34-4470-9255-335799595A1BQ37718385-9751ADB8-58F2-41C2-945E-A14ACF460EADQ37827345-A798EA03-F501-4791-A790-136D827AD92DQ37888751-6D9AF28A-EFA0-4CCB-A5E2-1C2CFF1C556DQ37974743-523C0490-DBAC-4EC6-A619-1F57782DFFC7Q38586680-04E9FAB0-8F35-4EE8-9883-357204FC26EFQ38633102-16CFC2BA-6651-41EE-BF7C-8D38D193B8FCQ41990022-92607E84-5C83-43A2-8272-4FC3C016EE9AQ42119802-C1A3D836-0F1F-41E1-91E5-9570CA8B0BC9Q42845954-1B14DC03-A527-4F11-A11E-121C1A0E402B
P2860
In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
In vitro pharmacodynamics of a ...... ed caspofungin susceptibility.
@en
In vitro pharmacodynamics of a ...... ed caspofungin susceptibility.
@nl
type
label
In vitro pharmacodynamics of a ...... ed caspofungin susceptibility.
@en
In vitro pharmacodynamics of a ...... ed caspofungin susceptibility.
@nl
prefLabel
In vitro pharmacodynamics of a ...... ed caspofungin susceptibility.
@en
In vitro pharmacodynamics of a ...... ed caspofungin susceptibility.
@nl
P2093
P2860
P356
P1476
In vitro pharmacodynamics of a ...... sed caspofungin susceptibility
@en
P2093
David S Burgess
Jason Cota
John R Graybill
Laura K Najvar
Michael Carden
P2860
P304
P356
10.1128/AAC.00538-06
P407
P577
2006-08-28T00:00:00Z